Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide
Author:
Affiliation:
1. Eli Lilly and Company, Lilly Corporate Center; Indianapolis Indiana
2. Lilly USA, LLC, Lilly Corporate Center; Indianapolis Indiana
3. Eli Lilly Canada Inc., Toronto; Ontario Canada
4. Truven Health Analytics, an IBM Company; Ann Arbor Michigan
Funder
Truven Health Analytics
Eli Lilly and Company
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12902/fullpdf
Reference43 articles.
1. Beta cell dysfunction and insulin resistance;Cerf;Front Endocrinol (Lausanne),2013
2. Centers for Disease Control and Prevention National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014 Atlanta, GA US Department of Health and Human Services 2014
3. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study;Gregg;Lancet Diabetes Endocrinol,2014
4. Pharmacotherapy of type 2 diabetes mellitus: navigating current and new therapies;Lew;Medsurg Nurs,2015
5. Standards of medical care in diabetes-2016;American Diabetes Association;Diabetes Care,2016
Cited by 86 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes;Diabetes, Obesity and Metabolism;2023-09-12
2. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants;Journal of Medicinal Chemistry;2023-08-30
3. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis;Frontiers in Endocrinology;2023-07-06
4. CETP and SGLT2 inhibitor combination therapy improves glycemic control;2023-06-16
5. Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide;Journal of Diabetes Research;2023-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3